For more than half a century, heparin and vitamin K antagonistshave defined anticoagulant therapy for the short-term and long-termmanagement, respectively, of thrombotic disorders of the venoussystem. The history of their development is instructive. In1922, at the annual meeting of the American Physiological Society,William H. Howell of Johns Hopkins Medical School presentedan extraction protocol for isolating heparin preparations. Dicoumarol,a bacterial antagonist of vitamin K in spoiled sweet clover,was recognized as the agent responsible for a fatal hemorrhagicdisease in livestock by Karl Link and Wilhelm Schoeffel of theUniversity of Wisconsin. In both . . . [Full Text of this Article]
Source Information
From the Division of Cardiology, University of Freiburg, Freiburg, Germany (J.L.); and the Cardiovascular Thombosis Center, Duke University Medical Center, Durham, NC (R.C.B.).
Related Letters:
Rivaroxaban for Thromboprophylaxis
Schuman E. P., Lippi G., Franchini M., Targher G., Lotke P. A., ten Cate H., Hamulyak K., Geerts W., the RECORD 1 and RECORD 3 Investigators , Lassen M. R., Ageno W., Turpie A. G.G., Lohrmann J., Becker R. C.
Extract |
Full Text |
PDF
N Engl J Med 2008;
359:2174-2176, Nov 13, 2008.
Correspondence
This article has been cited by other articles:
Levine, M. N.
(2009). New Antithrombotic Drugs: Potential for Use in Oncology. JCO
27: 4912-4918
[Abstract][Full Text]
Schuman, E. P., Lippi, G., Franchini, M., Targher, G., Lotke, P. A., ten Cate, H., Hamulyak, K., Geerts, W., the RECORD 1 and RECORD 3 Investigators, , Lassen, M. R., Ageno, W., Turpie, A. G.G., Lohrmann, J., Becker, R. C.
(2008). Rivaroxaban for Thromboprophylaxis. NEJM
359: 2174-2176
[Full Text]
Previous
